Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

chronic myeloid leukemia

This page shows the latest chronic myeloid leukemia news and features for those working in and with pharma, biotech and healthcare.

Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial

Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial

Drug improved major molecular response compared to existing med. Novartis experimental drug asciminib beat Pfizer’s Bosulif in a phase 3 trial in previously-treated chronic myeloid leukaemia (CML) patients, offering ... patients with newly diagnosed

Latest news

  • FDA approval for Kisqali sets up showdown with Ibrance FDA approval for Kisqali sets up showdown with Ibrance

    Novartis has experience of marketing drugs with QT prolongation, a side effect which affects its chronic myeloid leukemia (CML) therapy Tasigna (nilotinib) but has not stopped the drug from becoming a

  • EMA safety panel rules no change needed for Ariad's Iclusig EMA safety panel rules no change needed for Ariad's Iclusig

    Iclusig was approved in the US and EU last year for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), but ... independent studies in other indications,

  • Novartis provides multimedia support to Rare Diseases Day Novartis provides multimedia support to Rare Diseases Day

    The initiative includes fact sheets, infographics and advice on diseases such as  Cushing's disease, gastrointestinal stromal tumor (GIST), chronic myeloid leukemia etc.

  • Novartis posts strong Q1 2011 results

    However, sales of Tasigna in its primary indication as a targeted therapy for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), increased by over 100 per cent to $153m in Q1. .

  • Leukemia treatment approved

    The US FDA has granted full approval for Bristol-Myers Squibb's Sprycel for the treatment of adults in all phases of chronic myeloid leukemia. ... The US Food and Drug Administration (FDA) has granted full approval for Bristol-Myers Squibb's Sprycel

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There are also global direct-to-patient access programmes for Gleevec and Tasigna, life-saving therapies for chronic myeloid leukemia and gastrointestinal stromal tumours. ... The elderly population is growing rapidly in these countries, too, driving a

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...

Quick links